TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24670351

Group type: EXPERIMENTAL
Intervention: Krka's formulation of clopidogrel under fasting conditions
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Krka's formulation of clopidogrel under fed conditions
Number of subjects: 205

Group type: COMPARATOR
Intervention: Innovator's formulation of clopidogrel under fasting conditions
Number of subjects: 205

Group type: COMPARATOR
Intervention: Innovator's formulation of clopidogrel under fed conditions
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both formulations of clopidogrel
Number of subjects: 205
Study: 23168362

Group type: COMPARATOR
Intervention: FOLFOX4
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: bevacizumab-FOLFOX4
Number of subjects: 3451

Group type: EXPERIMENTAL
Intervention: bevacizumab-XELOX
Number of subjects: 3451
Study: 20360152

Group type: EXPERIMENTAL
Intervention: Physiotherapist-supervised exercise programme
Number of subjects: 30

Group type: COMPARATOR
Intervention: Self-supervised home exercise programme
Number of subjects: 30
Study: 17316845

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 62

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison of Levosimendan vs Dobutamine
Number of subjects: 62
Study: 16212577

Group type: EXPERIMENTAL
Intervention: 2(1/2) min. brushing
Number of subjects: 45

Group type: COMPARATOR
Intervention: 2 min. brushing
Number of subjects: 45
Study: 11951812

Group type: EXPERIMENTAL
Intervention: Controlled-release alpha-lipoic acid (CRLA) 900 mg daily for 6 weeks, then 1200 mg daily for an additional 6 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Controlled-release alpha-lipoic acid (CRLA)
Number of subjects: 21
Study: 10402336

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 1.5 mg/kg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine 2 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 8918852

Group type: EXPERIMENTAL
Intervention: Educational intervention addressing AAS effects, sports nutrition, strength-training alternatives, drug refusal role play, anti-AAS media messages, and weight-room sessions.
Number of subjects: 1506

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 1506
Study: 1833800

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: xipamide
Number of subjects: 42
Study: 6130151

Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Temazepam
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29595341

Group type: EXPERIMENTAL
Intervention: Ragi porridge supplementation for 90 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no ragi porridge)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ragi porridge supplementation
Number of subjects: 60
Study: 29061598

Group type: EXPERIMENTAL
Intervention: Household conditional cash transfer programme (CCT)
Number of subjects: 6869
Study: 25705007

Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 261
Study: 24265036

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 22552025

Group type: EXPERIMENTAL
Intervention: Lifestyle + limited variety (LV)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Lifestyle
Number of subjects: 202
Study: 19938957

Group type: EXPERIMENTAL
Intervention: hMG and hCG
Number of subjects: 60
Study: 17563129

Group type: EXPERIMENTAL
Intervention: Lidocaine 20mg plus remifentanil 0.3 microg/kg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Lidocaine 20mg
Number of subjects: 129

Group type: COMPARATOR
Intervention: Remifentanil 0.3 microg/kg
Number of subjects: 129
Study: 15062906

Group type: EXPERIMENTAL
Intervention: Preoperative education using a planned teaching method according to the patient education booklet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group receiving information about pre‐ and postoperative routines from a nurse
Number of subjects: 100
Study: 11475176

Group type: EXPERIMENTAL
Intervention: 33% oxygen in nitrogen (2.5 L/min air with 0.5 L/min oxygen)
Number of subjects: 62

Group type: COMPARATOR
Intervention: 33% oxygen in nitrous oxide (2 L/min nitrous oxide and 1 L/min oxygen)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Crying during induction
Number of subjects: 62
Study: 9893601

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) for eubacterial genome
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Polymerase chain reaction (PCR) for Propionibacterium acnes (P acnes)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (non-infective disorders)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Inclusion of PCR in diagnosis
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: PCR on AH
Number of subjects: 55
Study: 9609217

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjusted dose heparin or warfarin
Number of subjects: 0
Study: 2376845

Group type: EXPERIMENTAL
Intervention: Induced 'harmful' anticipation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ergometer capacity test at 40 and 80 watt
Number of subjects: 32

Group type: COMPARATOR
Intervention: Experimental variables (harmful vs non-harmful instructions)
Number of subjects: 32
Study: 503385

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) gel (0.5 mg PGE2) intracervically
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oxytocin intravenously
Number of subjects: 100
Study: 30985195

Group type: EXPERIMENTAL
Intervention: AMVCCT (Alberta Motor Vehicle Collision Culpability Tool)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Culpable drivers (rated by AMVCCT)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Non-culpable drivers (rated by AMVCCT)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Culpable drivers (gender comparison)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Culpable drivers (alcohol impairment comparison)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Culpable drivers (age comparison)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Culpable drivers (time of day comparison)
Number of subjects: 175
Study: 27671974

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25981818

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 23252716

Group type: EXPERIMENTAL
Intervention: Thioguanine
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Number of subjects: 1150

Group type: COMPARATOR
Intervention: TPMT activity at diagnosis
Number of subjects: 1150

Group type: COMPARATOR
Intervention: TPMT genotype-phenotype concordance
Number of subjects: 1150

Group type: COMPARATOR
Intervention: TPMT intermediate activity patients with wild-type genotype
Number of subjects: 1150
Study: 21129895

Group type: EXPERIMENTAL
Intervention: Aberdeen Varicose Vein Questionnaire (AVVQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional, clinical, and hemodynamic measurements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-specific quality-of-life measures (AVVQ and SQOR-V)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anatomical and hemodynamic measurements
Number of subjects: 0
Study: 20108194

Group type: EXPERIMENTAL
Intervention: Scleral Buckling (SBS)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Primary Vitrectomy (PV)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Surgeon factor
Number of subjects: 681
Study: 17513655

Group type: EXPERIMENTAL
Intervention: Combination group (lidocaine and remifentanil)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Remifentanil group
Number of subjects: 156

Group type: COMPARATOR
Intervention: Lidocaine group
Number of subjects: 156
Study: 15581385

Group type: EXPERIMENTAL
Intervention: Seglor (dihydroergotamine mesilate)
Number of subjects: 363

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study: 11556052

Group type: EXPERIMENTAL
Intervention: Clinical Practice Improvement (CPI) methodology
Number of subjects: 0
Study: 9793011

Group type: EXPERIMENTAL
Intervention: Group interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 7986517

Group type: EXPERIMENTAL
Intervention: Forced-air warmer (Bair Hugger)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (400W heat lamp)
Number of subjects: 51
Study: 3044503

Group type: EXPERIMENTAL
Intervention: Cyclopenthiazide 125 micrograms
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cyclopenthiazide 500 micrograms
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31914963

Group type: EXPERIMENTAL
Intervention: Nintedanib (INPULSIS)
Number of subjects: 638

Group type: EXPERIMENTAL
Intervention: Nintedanib (INSTAGE)
Number of subjects: 638

Group type: COMPARATOR
Intervention: Placebo (INPULSIS)
Number of subjects: 638
Study: 31633257

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rtfMRI-nf) signal
Number of subjects: 27

Group type: COMPARATOR
Intervention: Sham neurofeedback signal
Number of subjects: 27
Study: 28045940

Group type: EXPERIMENTAL
Intervention: Intervention group (modified virtual ward model)
Number of subjects: 840

Group type: COMPARATOR
Intervention: Control group (standard hospital care)
Number of subjects: 840
Study: 26085303

Group type: EXPERIMENTAL
Intervention: 24 h of total sleep deprivation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular sleep‐wake cycle (Control)
Number of subjects: 50
Study: 21636144

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment
Number of subjects: 4951

Group type: EXPERIMENTAL
Intervention: Risk score stratification
Number of subjects: 4951

Group type: EXPERIMENTAL
Intervention: Risk score calibration and discrimination
Number of subjects: 4951

Group type: EXPERIMENTAL
Intervention: Subgroup stratification
Number of subjects: 4951
Study: 21129028

Group type: EXPERIMENTAL
Intervention: Lactulose (Group-L)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No lactulose (Group-P)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lactulose therapy
Number of subjects: 70
Study: 16704585

Group type: EXPERIMENTAL
Intervention: Modified Position group (lateral position, 20 degrees head-down tilt)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Supine group
Number of subjects: 72
Study: 15641635

Group type: EXPERIMENTAL
Intervention: Care map intervention with individual instruction and training sessions for parents
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (regular care without additional training)
Number of subjects: 42
Study: 11422660

Group type: EXPERIMENTAL
Intervention: Nicotine infusion (0.3 microg kg‐1 min(‐1))
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (NaCl infusion)
Number of subjects: 6
Study: 9415651

Group type: EXPERIMENTAL
Intervention: Computerized version of WOMAC VA3.0
Number of subjects: 30

Group type: COMPARATOR
Intervention: Paper version of WOMAC
Number of subjects: 30
Study: 7693420

Group type: EXPERIMENTAL
Intervention: FEC 50 x 6 cycles (Group A, n = 207)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: FEC 50 x 3 cycles (Group B, n = 193)
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: FEC 75 x 3 cycles (Group C, n = 195)
Number of subjects: 621
Study: 3027884

Group type: EXPERIMENTAL
Intervention: Tinidazole treatment for 5 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control without placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tinidazole treatment
Number of subjects: 24
Study: 31535332

Group type: EXPERIMENTAL
Intervention: Oral probiotic (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29889698

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (1 mg) with 15 mL bupivacaine 0.5%
Number of subjects: 125

Group type: COMPARATOR
Intervention: Intravenous dexamethasone (1 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Both groups (PeriD and IVDex)
Number of subjects: 125
Study: 26280313

Group type: EXPERIMENTAL
Intervention: Active stimulation with foc.us tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 24
Study: 24948800

Group type: EXPERIMENTAL
Intervention: Dynamic structure of motion detectors in native space-time; amplitude change over the first ∼100 ms.
Number of subjects: 0
Study: 22728230

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (plus cyclic medroxyprogesterone)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 69

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Adolescents with AN
Number of subjects: 69
Study: 20099269

Group type: EXPERIMENTAL
Intervention: MDD+PAS (Major Depressive Disorder plus Panic-Agoraphobic Spectrum Disorders)
Number of subjects: 97

Group type: COMPARATOR
Intervention: MDD (Major Depressive Disorder)
Number of subjects: 97
Study: 17883554

Group type: EXPERIMENTAL
Intervention: Merocel pack
Number of subjects: 21

Group type: COMPARATOR
Intervention: Series 5000 pack
Number of subjects: 21
Study: 16351359

Group type: EXPERIMENTAL
Intervention: APOE-epsilon4 gene dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (noncarriers and heterozygotes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APOE-epsilon4 homozygotes
Number of subjects: 0
Study: 12542203

Group type: EXPERIMENTAL
Intervention: Exercise subjects (active and passive head movements, walking with augmented head movements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (attention without exercise)
Number of subjects: 0
Study: 9706600

Group type: EXPERIMENTAL
Intervention: Meropenem (1 g/8 h)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cefotaxime (2 g/8 h) plus Metronidazole (0.5 g/8 h)
Number of subjects: 98
Study: 8521151

Group type: EXPERIMENTAL
Intervention: Fluoxetine (60 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2677125

Group type: EXPERIMENTAL
Intervention: lofepramine (70 mg, 105 mg, 140 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: amitriptyline (50 mg)
Number of subjects: 6
Study: 699626

Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: 750 mg aspirin 4-times daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: 600 mg aspirin 4-times daily
Number of subjects: 22
Study: 30705241

Group type: EXPERIMENTAL
Intervention: Dysarthria therapy via Skype (3 sessions of 40 min per week for 6 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as usual (usual speech therapy from local therapist for 6 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dysarthria therapy via Skype
Number of subjects: 22
Study: 28888207

Group type: EXPERIMENTAL
Intervention: Modified lunge stretching
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multidirectional stretching
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Joint mobilization stretching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Passive static stretching
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 25516993

Group type: EXPERIMENTAL
Intervention: Oxygen supply via nasal cannula at a flow of 4 L/min
Number of subjects: 36

Group type: COMPARATOR
Intervention: Compressed air at a flow of 4 L/min
Number of subjects: 36
Study: 24196599

Group type: EXPERIMENTAL
Intervention: Individual step count goal-setting
Number of subjects: 136

Group type: COMPARATOR
Intervention: Control group (no goal-setting)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 136
Study: 21068204

Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Taboka
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Medicinal Nicotine
Number of subjects: 130
Study: 19847319

Group type: EXPERIMENTAL
Intervention: Undenatured type II collagen (UC‐II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucosamine and chondroitin (G+C)
Number of subjects: 0
Study: 16460691

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Daytime prazosin (open label)
Number of subjects: 11
Study: 15307813

Group type: EXPERIMENTAL
Intervention: Background music (45-minute CD at naptime and bedtime for 3 weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no background music)
Number of subjects: 86
Study: 11298047

Group type: EXPERIMENTAL
Intervention: Posterior retroperitoneoscopic approach (RPA)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lateral retroperitoneoscopic approach (RPA)
Number of subjects: 55
Study: 9422296

Group type: EXPERIMENTAL
Intervention: Fentanyl (2.5 microg x kg(‐1)) plus thiopentone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Complete muscle relaxation (> or =65%)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Complete muscle relaxation (100%)
Number of subjects: 60
Study: 8351758

Group type: EXPERIMENTAL
Intervention: Single dose prophylaxis with ciprofloxacin (500 mg)
Number of subjects: 235

Group type: COMPARATOR
Intervention: 3-day prophylaxis with ciprofloxacin
Number of subjects: 235
Study: 3304613

Group type: EXPERIMENTAL
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Velban, Actinomycin‐D, bleomycin, cisplatin, and cytoxan (VAB‐6)
Number of subjects: 0
Study: 30876973

Group type: EXPERIMENTAL
Intervention: Atrasentan (Atr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High glucose (HG) treatment
Number of subjects: 0
Study: 29526235

Group type: EXPERIMENTAL
Intervention: Aromatherapy with Rosa damascena (0.08 mL every 30 min)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal saline (0.08 mL every 30 min)
Number of subjects: 110
Study: 26503310

Group type: EXPERIMENTAL
Intervention: 1 hour supervised exercise training, 3 days/week for 8 weeks (n=10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Equal-time health education training, 3 days/week for 8 weeks (n=9)
Number of subjects: 19
Study: 25176266

Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation of blood (ILIB) with semiconductor laser (wavelength - 0.67 microns, power output - 3-2 mW) in addition to standard treatment
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Intravenous laser irradiation of blood (ILIB) with semiconductor laser
Number of subjects: 53
Study: 22982824

Group type: EXPERIMENTAL
Intervention: Intensive strengthening exercise
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard physical therapy (stretching and gait training)
Number of subjects: 44
Study: 20434060

Group type: EXPERIMENTAL
Intervention: Environmental change (introduction of 10 new low‐energy‐density foods and provision of labels for all foods sold at lunch)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Environmental change plus pricing incentives and education about low‐ED eating
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both groups (environmental change and environmental change plus pricing incentives)
Number of subjects: 96
Study: 17564201

Group type: EXPERIMENTAL
Intervention: Bare finger
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rigid stylus-shaped probe
Number of subjects: 0
Study: 15059282

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for one week, with weaning over a second week)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (identical appearing)
Number of subjects: 40
Study: 11384567

Group type: COMPARATOR
Intervention: Pilocarpine (2%) four times daily to one eye and vehicle to the other
Number of subjects: 30

Group type: COMPARATOR
Intervention: Latanoprost (0.005%) once daily to both eyes
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined treatment of pilocarpine and latanoprost
Number of subjects: 30

Group type: COMPARATOR
Intervention: Latanoprost (0.005%) once daily to one eye and vehicle to the other
Number of subjects: 30
Study: 9223193

Group type: EXPERIMENTAL
Intervention: Nesacaine-CE 3%
Number of subjects: 30

Group type: COMPARATOR
Intervention: lidocaine 1.33%
Number of subjects: 30
Study: 7967363

Group type: EXPERIMENTAL
Intervention: Icodextrin (D)
Number of subjects: 209

Group type: COMPARATOR
Intervention: 1.36% glucose (C)
Number of subjects: 209

Group type: COMPARATOR
Intervention: 3.86% glucose (C)
Number of subjects: 209
Study: 3606916

Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 93
Study: 30085184

Group type: EXPERIMENTAL
Intervention: Dual therapy (DT) with a ritonavir‐boosted PI (PI/r) plus lamivudine
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Triple therapy (TT) with PI/r plus two nucleos(t)ide reverse transcriptase inhibitors (N(t)RTIs)
Number of subjects: 1051
Study: 27806977

Group type: EXPERIMENTAL
Intervention: Choline supplementation (625 mg/d for 6 weeks)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo (equivalent inactive treatment)
Number of subjects: 55
Study: 24865619

Group type: EXPERIMENTAL
Intervention: Contingency management treatment
Number of subjects: 428
Study: 23001240

Group type: EXPERIMENTAL
Intervention: Serum iron metrics (including serum ferritin, serum iron, transferrin saturation, TIBC)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Serum ferritin, serum iron, transferrin saturation, TIBC
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Dietary iron exposures
Number of subjects: 341
Study: 20798364

Group type: EXPERIMENTAL
Intervention: Upper Extremity Thermal Stimulation (UE-TS) for 30 minutes per day, 3 days/week for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Lower Extremity Thermal Stimulation (Control)
Number of subjects: 23
Study: 18447214

Group type: EXPERIMENTAL
Intervention: Acupuncture at Neiguan (PC 6), Zusanli (ST 36), Sanyinjiao (SP 6)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group treated with oral administration of Weilexin
Number of subjects: 60